Agios Pharmaceuticals, Inc.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving Agios Pharmaceuticals, Inc. now
Current reporting with the operating signal separated from the noise.
Bronstein, Gewirtz & Grossman, LLC Encourages Agios Pharmaceuticals, Inc. (AGIO) Investors to Inquire about Securities Investigation
The story matters when it changes Agios Pharmaceuticals, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Agios Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:AGIO) 2026-07-30
Investors are testing whether Agios Pharmaceuticals, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO
The development tests whether Agios Pharmaceuticals, Inc. can turn product investment into adoption, revenue and durable advantage.
Watch next: confirmation in a company filing, official release or regulator record.Agios Pharmaceuticals, Inc. (AGIO) Q2 2026 Earnings Call Transcript
Investors are testing whether Agios Pharmaceuticals, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Earnings Flash (AGIO) Agios Pharmaceuticals, Inc. Reports Q2 Revenue $44.7M, vs. FactSet Est of $26.4M
Investors are testing whether Agios Pharmaceuticals, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Agios Pharmaceuticals, Inc.: Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease
The story matters when it changes Agios Pharmaceuticals, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Agios Pharmaceuticals, Inc.: Agios Reports Second Quarter 2026 Financial Results and Provides Business Update
The story matters when it changes Agios Pharmaceuticals, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Agios Pharmaceuticals, Inc. (AGIO) Q1 FY2026 earnings call transcript
Investors are testing whether Agios Pharmaceuticals, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Latest AGIO filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
Agios Pharmaceuticals, Inc., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
SEARCH Q1 COVERAGE →Second quarter
Third quarter
No verified period-specific item in the current feed.
SEARCH Q3 COVERAGE →Fourth quarter / full year
No verified period-specific item in the current feed.
SEARCH Q4 COVERAGE →